CONNECT BIOPHARMA HOLDINGS LIMITED - AMERICAN DEPO

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

17 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Participate at the Jefferies Healthcare Conference

02 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

17 May 2022 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

03 May 2022 16:05:01 By Nasdaq GlobeNewswire

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

31 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

01 Mar 2022 08:00:15 By Nasdaq GlobeNewswire

Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

09 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference

24 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

05 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201

04 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer

22 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

19 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

18 Nov 2021 16:02:00 By Nasdaq GlobeNewswire

Connect Biopharma to Participate at Upcoming Conferences

11 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

19 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps

08 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

31 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021

25 Aug 2021 08:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

23 Aug 2021 16:05:00 By Nasdaq GlobeNewswire